ClearPoint Neuro, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights:

• 2025 is a strategic transformation for ClearPoint Neuro, with two new strategy phases: 'fast forward' (penetrating existing markets) and 'Essential Everywhere' (building a new $10 billion+ addressable market in neuro drug delivery).
• Announced merger with IRRAS, which has the IRRAflow platform with $9 million run rate, 83% YTD growth, and mid-50s gross margins. Strategic rationales include access to intracranial fluid management market, launching longer duration infusion cannulas, and gaining operational scale with an expanded commercial team.
• Q3 2025 financials: Total revenue $8.9 million (9% growth Y/Y). Gross margin 63% (up from 60% Y/Y). R&D costs $3.5 million (+4% Y/Y), sales and marketing $3.8 million (+8% Y/Y), general and administrative $3.6 million (+14% Y/Y). Cash and cash equivalents $38.2 million as of Sept 30, 2025.
• Transition to new CRO facility in Torrey Pines affected Q3 growth, but biologics and drug delivery expected to return to double-digit growth in Q4 and accelerate in 2026-2027.

Segment Performance:

• Biologics and drug delivery: Revenue was $4.4 million in Q3 2025, relatively consistent.
• Neurosurgery navigation therapy: Grew 20% to $3.4 million in Q3 2025, driven by higher sales of PRISM Laser Therapy and the introduction of the 3.0 operating room navigation software.
• Capital equipment and software: Increased 25% to $1 million in Q3 2025 from sales of ClearPoint navigation hardware and software.
• IRRAS: Had an estimated $9 million run rate with a September year-to-date growth rate of 83% and gross margins in the mid-50s. The IRRAflow catheter gives ClearPoint access to a large existing market in intracranial fluid management, estimated at up to ~400,000 procedures annually in the US and ~$0.5 billion market opportunity.

Guidance:

• Narrowed full-year 2025 revenue forecast to $36 million to $38 million.
• Pro forma revenue guidance for 2026 is between $54 million and $60 million, with additional update planned in mid-January after IRRAS transaction closure and integration.
• IRRAS has mid-50s gross margins, and ClearPoint expects to achieve 70%+ gross margins at scale. Burn profile expected to have integration costs in Q4 and Q1, with plans to reduce burn meaningfully over time.

Risks:

• Forward-looking statements subject to actual results differing materially. Risks include uncertainties related to clinical trial outcomes, regulatory approvals, market adoption of new products, and integration challenges from the IRRAS merger.

Q: Frank Takkinen also asked about the current quarter's CRO site impact, magnitude of potential orders, and timing.

A: Joseph Burnett said the new CRO facility allows for larger studies (up to 4-5x past size), higher value GLP studies, and additional services for pharma partners, with plans to fully execute higher-margin GLP studies next year and more comprehensive services by early Q1.